Palvella Therapeutics Inc.

02/10/2025 | Press release | Distributed by Public on 02/10/2025 07:25

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.